Capillary leak syndrome in children who undergo cardiopulmonary bypass: Clinical outcome in comparison with complement activation and C1 inhibitor

Intensive Care Medicine

Volumn 27, Issue 1, 2001, Pages 193-200

  Stiller, Brigitte ^a   Sonntag, Josef ^b   Dähnert, Ingo ^a   Alexi Meskishvili, Vladimir ^a   Hetzer, Roland ^a   Fischer, Thomas ^a   Lange, Peter E ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

C1 esterase inhibitor; Capillary leak syndrome; Cardiopulmonary bypass; Complement system; Contact system; Infants

Indexed keywords

BLOOD CLOTTING FACTOR 12A; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; PREKALLIKREIN;

ARTICLE; BODY WEIGHT; CAPILLARY LEAK SYNDROME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONGENITAL HEART DISEASE; FEMALE; HUMAN; HYPOTHERMIA; INFANT; MALE; OPEN HEART SURGERY; PROTEIN EXPRESSION; SEX DIFFERENCE;

CAPILLARY LEAK SYNDROME; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; MALE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0035091858     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340000704     Document Type: Article

References (36)

1. Aspects of biocompability in cardiopulmonary bypass
2. Organ dysfunction and cardiopulmonary bypass: The role of complement and complement regulatory proteins
3. Assessing the effect of cardiopulmonary bypass on the brain
4. Complement and the damaging effects of cardiopulmonary bypass
5. Complement activation during cardiopulmonary bypass in infants and children
6. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations
7. Complement and contact activation during cardiovascular operations in infants
8. Cytokine and complement levels in patients undergoing cardiopulmonary bypass
9. Ultrafiltration and modified ultrafiltration in pediatric open heart operations
10. Reduced complement activation with heparin-coated oxygenator and tubing in coronary bypass operations
11. Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins
12. The membrane attack complex
13. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass
14. Complement activation by heparin-protamine complexes during cardiopulmonary bypass: Effect of C4 A null allele
15. Formation of Cls-C1-inhibitor, kallikrein C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass
16. The contact activation system of plasma
17. Development of a rapid kinetic assay for the function of the classical pathway of the complement system and for C2 and CA
18. Complement system in healthy term newborns: Reference values in umbilical cord blood
19. Immunochemical quantitation of antigens by single radial immunodiffusion
20. A chromogenic substrate assay for C1-inhibitor
21. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies
22. Methodological considerations on chromogenic peptide substrate assays and applications on automated analysis
23. An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hagman factor) in human plasma
24. Complement activation during cardiopulmonary bypass in children
25. Prolonged open sternotomy after pediatric heart operation: Experience with 113 patients
26. Surface mediated defense mechanisms. The plasma contact activation system
27. The role of plasma proteases in septic shock
28. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome
29. Complement activation during bypass in acquired C1 esterase inhibitor deficiency
30. Cardiopulmonary bypass in a patient with acquired C1 inhibitor deficiency
31. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement
32. Capillary leak syndrome after open heart surgery for congenital heart defects: Therapy with C1-inhibitor
33. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion
34. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2
35. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion
36. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA